» Articles » PMID: 32612138

Reduced Replication Origin Licensing Selectively Kills KRAS-mutant Colorectal Cancer Cells Via Mitotic Catastrophe

Abstract

To unravel vulnerabilities of KRAS-mutant CRC cells, a shRNA-based screen specifically inhibiting MAPK pathway components and targets was performed in CaCo2 cells harboring conditional oncogenic KRAS. The custom-designed shRNA library comprised 121 selected genes, which were previously identified to be strongly regulated in response to MEK inhibition. The screen showed that CaCo2 cells expressing KRAS were sensitive to the suppression of the DNA replication licensing factor minichromosome maintenance complex component 7 (MCM7), whereas KRAS CaCo2 cells were largely resistant to MCM7 suppression. Similar results were obtained in an isogenic DLD-1 cell culture model. Knockdown of MCM7 in a KRAS-mutant background led to replication stress as indicated by increased nuclear RPA focalization. Further investigation showed a significant increase in mitotic cells after simultaneous MCM7 knockdown and KRAS expression. The increased percentage of mitotic cells coincided with strongly increased DNA damage in mitosis. Taken together, the accumulation of DNA damage in mitotic cells is due to replication stress that remained unresolved, which results in mitotic catastrophe and cell death. In summary, the data show a vulnerability of KRAS-mutant cells towards suppression of MCM7 and suggest that inhibiting DNA replication licensing might be a viable strategy to target KRAS-mutant cancers.

Citing Articles

Identification of ATP-Competitive Human CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function.

Xiang S, Craig K, Luo X, Welch D, Ferreira R, Lawrence H Mol Cancer Ther. 2024; 23(11):1568-1585.

PMID: 38982858 PMC: 11532780. DOI: 10.1158/1535-7163.MCT-23-0904.


BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.

Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J J Clin Invest. 2022; 132(22).

PMID: 36377663 PMC: 9663163. DOI: 10.1172/JCI161308.


Small Molecule Inhibitor Targeting CDT1/Geminin Protein Complex Promotes DNA Damage and Cell Death in Cancer Cells.

Karantzelis N, Petropoulos M, De Marco V, Egan D, Fish A, Christodoulou E Front Pharmacol. 2022; 13:860682.

PMID: 35548337 PMC: 9083542. DOI: 10.3389/fphar.2022.860682.


Targeting the DNA replication stress phenotype of KRAS mutant cancer cells.

Al Zubaidi T, Gehrisch O, Genois M, Liu Q, Lu S, Kung J Sci Rep. 2021; 11(1):3656.

PMID: 33574444 PMC: 7878884. DOI: 10.1038/s41598-021-83142-y.

References
1.
Papke B, Der C . Drugging RAS: Know the enemy. Science. 2017; 355(6330):1158-1163. DOI: 10.1126/science.aam7622. View

2.
Ostrem J, Peters U, Sos M, Wells J, Shokat K . K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013; 503(7477):548-51. PMC: 4274051. DOI: 10.1038/nature12796. View

3.
Janes M, Zhang J, Li L, Hansen R, Peters U, Guo X . Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018; 172(3):578-589.e17. DOI: 10.1016/j.cell.2018.01.006. View

4.
Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

5.
Filmus J, Robles A, Shi W, Wong M, Colombo L, Conti C . Induction of cyclin D1 overexpression by activated ras. Oncogene. 1994; 9(12):3627-33. View